ZURA BIO LIMITED Investing Cash Flow
ZURA BIO LIMITED (ZURA) reported Investing Cash Flow of -$37 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-11
- ZURA BIO LIMITED net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $12.96K, a 73.51% decline year-over-year.
- ZURA BIO LIMITED net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$13.00K.
- ZURA BIO LIMITED net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$17.00K.
- ZURA BIO LIMITED net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was -$95.94K.
- ZURA BIO LIMITED net cash provided by (used in) investing activities for fiscal 2025 was -$113.00K.
- ZURA BIO LIMITED net cash provided by (used in) investing activities for fiscal 2024 was -$5.08M.
- ZURA BIO LIMITED net cash provided by (used in) investing activities for fiscal 2023 was -$8.00M.
| Period end | Net Cash Provided by (Used in) Investing Activities 2 month | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 5 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 6 month as first filed | Net Cash Provided by (Used in) Investing Activities 7 month | Net Cash Provided by (Used in) Investing Activities 8 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 10 month | Net Cash Provided by (Used in) Investing Activities 11 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $12.96K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$37.00 10-Q · filed 2026-08-11 | -$17.04K derived: sum of 3 quarters · filed 2026-08-11 | -$112.97K derived: sum of 4 quarters · filed 2026-08-11 | |||||||
| 2026-03-31 | -$13.00K 10-Q · filed 2026-05-07 | -$30.00K derived: sum of 2 quarters · filed 2026-05-07 | -$125.94K derived: sum of 3 quarters · filed 2026-05-07 | -$77.00K derived: sum of 4 quarters · filed 2026-08-11 | |||||||
| 2025-12-31 | -$17.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$112.94K derived: sum of 2 quarters · filed 2026-03-19 | -$64.00K derived: sum of 3 quarters · filed 2026-08-11 | -$113.00K 10-K · filed 2026-03-19 | |||||||
| 2025-09-30 | -$95.94K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$47.00K derived: sum of 2 quarters · filed 2026-08-11 | -$96.00K 10-Q · filed 2025-11-13 | -$141.00K derived: sum of 4 quarters · filed 2026-08-11 | |||||||
| 2025-06-30 | $48.94K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$64.00 10-Q · filed 2026-08-11 | -$64.00K 10-Q · filed 2025-08-14 | -$45.06K derived: sum of 3 quarters · filed 2026-08-11 | -$58.06K derived: sum of 4 quarters · filed 2026-08-11 | ||||||
| 2025-03-31 | -$49.00K 10-Q · filed 2026-05-07 | -$94.00K derived: sum of 2 quarters · filed 2026-05-07 | -$107.00K derived: sum of 3 quarters · filed 2026-05-07 | -$117.00K derived: sum of 4 quarters · filed 2026-05-07 | |||||||
| 2024-12-31 | -$45.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$58.00K derived: sum of 2 quarters · filed 2026-03-19 | -$68.00K derived: sum of 3 quarters · filed 2026-03-19 | -$5.08M 10-K · filed 2026-03-19 | |||||||
| 2024-09-30 | -$13.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$23.00K derived: sum of 2 quarters · filed 2025-11-13 | -$5.03M 10-Q · filed 2025-11-13 | -$5.03M derived: sum of 4 quarters · filed 2025-11-13 | |||||||
| 2024-06-30 | -$10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$5.02M 10-Q · filed 2025-08-14 | -$5.02M derived: sum of 3 quarters · filed 2025-08-14 | -$7.27M derived: sum of 4 quarters · filed 2025-08-14 | |||||||
| 2024-03-31 | -$5.01M 10-Q · filed 2025-05-08 | -$5.01M derived: sum of 2 quarters · filed 2025-05-08 | -$7.26M derived: sum of 3 quarters · filed 2025-05-08 | ||||||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | -$2.25M derived: sum of 2 quarters · filed 2025-03-25 | -$8.00M 10-K · filed 2025-03-25 | ||||||||
| 2023-09-30 | -$2.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$8.00M 10-Q · filed 2024-11-07 | |||||||||
| 2023-06-30 | -$5.75M 10-Q · filed 2024-08-13 | ||||||||||
| 2022-12-31 | -$12.00M 10-K · filed 2024-03-28 | ||||||||||
| 2022-09-30 | -$5.00M 10-Q · filed 2023-11-13 | ||||||||||
| 2022-06-30 | -$5.00M 10-Q · filed 2023-08-14 | ||||||||||
| 2022-03-31 | -$5.00M 10-Q · filed 2023-05-12 | ||||||||||
| 2021-12-31 | -$139.38M 10-K · filed 2023-03-28 | ||||||||||
| 2021-09-30 | -$139.38M 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |